Amino acid ester prodrugs of floxuridine: Synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis

Pharmaceutical Research

Volumn 20, Issue 9, 2003, Pages 1381-1388

  Vig, Balvinder S ^a   Lorenzi, Philip J ^a   Mittal, Sachin ^a   Landowski, Christopher P ^a   Shin, Ho Chul ^a   Mosberg, Henry I ^a   Hilfinger, John M ^b   Amidon, Gordon L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TSRL INC   (United States)

Author keywords

Amino acid; Caco 2; Floxuridine; Hydrolysis; Prodrug; Stability

Indexed keywords

3' DEXTRO PHENYLALANYLFLOXURIDINE; 3' DEXTRO VALYLFLOXURIDINE; 3' PHENYLALANYLFLOXURIDINE; 3' PROLYLFLOXURIDINE; 3' VALYLFLOXURIDINE; 3',5' DEXTRO DIVALYLFLOXURIDINE; 3',5' DEXTRO PHENYLALANYLFLOXURIDINE; 3',5' DIPHENYLALANYLFLOXURIDINE; 3',5' DIPROLYLFLOXURIDINE; 3',5' DIVALYLFLOXURIDINE; 5' DEXTRO PHENYLALANYLFLOXURIDINE; 5' DEXTRO VALYLFLOXURIDINE; 5' PHENYLALANYLFLOXURIDINE; 5' PROLYLFLOXURIDINE; 5' VALYLFLOXURIDINE; FLOXURIDINE DERIVATIVE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG STRUCTURE; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; HUMAN CELL; PH; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; BUFFERS; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTERS; FLOXURIDINE; HUMANS; HYDROLYSIS; MOLECULAR STRUCTURE; PRODRUGS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141567450     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025745824632     Document Type: Article

References (29)

1. N. Kemeny, Y. Huang, A. M. Cohen, W. Shi, J. A. Conti, M. F. Brennan, J. R. Bertino, A. D. Turnbull, D. Sullivan, J. Stockman, L. H. Blumgart, and Y. Fong. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med. 341:2039-2048 (1999).
2. J. L. Grem. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest. New Drugs 18:299-313 (2000).
3. B. A. Chabner, D. P. Ryan, L. Paz-Area, R. Garcia-Carbonero, and P. Calabresi. Antineoplastic agents. In G. Hardman and L. E. Limbird (eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., Mc-Graw Hill, New York, 2001, pp. 1389-1459.
4. J. A. Van Laar, Y. M. Rustum, S. P. Ackland, C. J. Van Groeningen, and G. J. Peters. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer 34:296-306 (1998).
5. H. K. Han and G. L. Amidon. Targeted prodrug design to optimize drug delivery. AAPS Pharmsci. 2:E6 (2000).
6. W. A. Denny. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36:577-595 (2001).
7. R. A. Schwendener, A. Supersaxo, W. Rubas, H. G. Weder, H. R. Hartmann, H. Schott, A. Ziegler, and H. Hengartner. 5′-O-Palmitoyl- and 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine-novel lipophilic analogues of 5′-fluoro-2′-deoxyuridine: Synthesis, incorporation into liposomes and preliminary biological results. Biochem. Biophys. Res. Commun. 126:660-666 (1985).
8. S. Fukushima, T. Kawaguchi, M. Nishida, K. Juni, Y. Yamashita, M, Takahashi, and M. Nakano. Selective anticancer effects of 3′,5′ -dioctanoyl-5-fluoro-2′-deoxyuridine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing vx-2 tumor. Cancer Res. 47:1930-1934 (1987).
9. T. Kawaguchi, S. Fukushima, Y. Hayashi, and M. Nakano. Non-enzymatic and enzymatic hydrolysis of 5-fluoro-2′-deoxyuridine (FUdR) esters. Pharm. Res. 5:741-744 (1988).
10. T. Halmos, P. Moroni, K. Antonakis, and J. Uriel. Fatty acid conjugates of 2′-deoxy-5-fluorouridine as prodrugs for the selective delivery of 5-fluorouracil to tumor cells. Biochem. Pharmacol. 44:149-155 (1992).
11. S. C. Tobias and R. F. Borch. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J. Med. Chem. 44:4475-4480 (2001).
12. Y. Wei, Y. Van, D. Pei, and B. Gong. A photoactivated prodrug. Bioorg. Med. Chem. Lett. 8:2419-2422 (1998).
13. Z. Xia, L. I. Wiebe, G. G. Miller, and E. E. Knaus. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2′ -deoxyuridine and 2′,5-difluoro-2′-deoxyuridine as potential dual action anticancer prodrugs. Arch. Pharm. (Weinheim) 332:286-294 (1999).
14. H. K. Han, D. M. Oh, and G. L. Amidon. Cellular uptake mechanism of amino acid ester prodrugs in caco-2/hpept1 cells overexpressing a human peptide transporter. Pharm. Res. 15:1382-1386 (1998).
15. I. Rubio-Aliaga and H. Daniel. Mammalian peptide transporters as targets for drug delivery. Trends Pharmacol. Sci. 23:434-440 (2002).
16. D. M. Oh, H. Han, and G. L. Amidon. Drug transport and targeting. Intestinal transport. Pharm. Biotechnol. 12:59-88 (1999).
17. M. Sugawara, W. Huang, Y. L. Fei, F. H. Leibach, V. Ganapathy, and M. E. Ganapathy. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters pept1 and pept2. J. Pharm. Sci. 89:781-789 (2000).
18. T. Nakanishi, I. Tamai, A. Takaki, and A. Tsuji. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 88:274-280 (2000).
19. D. E. Gonzalez, K. M. Covitz, W. Sadee, and R. J. Mrsny. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines aspc-1 and capan-2. Cancer Res. 58:519-525 (1998).
20. R. J. Mrsny. Oligopeptide transporters as putative therapeutic targets for cancer cells. Pharm. Res. 15:816-818 (1998).
21. V. H. Lee. Mucosal drug delivery. J. Natl. Cancer Inst. Monogr. 41:4 (2001).
22. F. M. Williams. Clinical significance of esterases in man. Clinical Pharmacokin. 10:392-403 (1985).
23. P. K. Banerjee and G. L. Amidon. Design of prodrugs based on enzyme-substrate specificity. In H. Bundgaard (ed.), Design of Prodrugs, Elsevier, Sciences Publisher, New York, 1985, pp. 93-133.
24. T. Satoh, P. Taylor, W. F. Bosron, S. P. Sanghani, M. Hosokawa, and B. N. La Du. Current progress on esterases: From molecular structure to function. Drug Metab. Dispos. 30:488-493 (2002).
25. S. A. Varia, S. Schuller, and V. J. Stella. Phenytoin prodrugs iv: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters. J. Pharm. Sci. 73:1074-1080 (1984).
26. T. C. Bruice and S. Benkovic. Bioorganic mechanisms, W. A. Benjamin, Inc., New York (1966).
27. R. Wolfenden. The mechanism of hydrolysis of amino acyl RNA. Biochemistry 2:1090-1092 (1963).
28. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749 (1989).
29. K. Tamura, C. P. Lee, P. L. Smith, and R. T. Borchardt. Metabolism, uptake, and transepithelial transport of the stereoisomers of val-val-val in the human intestinal cell line, caco-2. Pharm. Res. 13:1663-1667 (1996).